Clinical Trial Update: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating alisertib in combination with vorinostat in adults with relapsed or recurrent Hodgkin lymphoma, B-cell non-Hodgkin lymphoma, or periphe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Anaplastic Large Cell Lymphoma
• B-cell Non-hodgkin Lymphoma
• Burkitt Lymphoma
• Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue
• Hodgkin Lymphoma
• Peripheral T-cell Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Alisertib (alisertib)
• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia | Phase 1 | Status: COMPLETED